http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114685612-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41d42dda56335b56f7f1545dcbc7ca22 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate | 2022-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d685cf6216509697a6db62b4e1ed2ba4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2850cef03b7e1fc230ae25ae94d5d8c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7b006720a351afc32f4b462c95780d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1722e643ceca36b4955871041c71a5e2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f3a3e45916a4cdb56dadc1a6b3c578a6 |
| publicationDate | 2022-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-114685612-A |
| titleOfInvention | A class of polypeptide inhibitors that block the binding of PD-1/PD-L1 and its application |
| abstract | The invention provides a class of polypeptide inhibitors that block the binding of PD-1/PD-L1 and applications thereof. The present invention synthesizes the polypeptide by means of solid-phase peptide, swells and deprotects the resin of the connected first amino acid, condenses the next amino acid, and so on, obtains the resin peptide and cuts it to obtain the polypeptide. By examining the inhibitory effect of the polypeptide on PD-1/PD-L1 protein binding in vitro, the anti-tumor effect in vitro and in vivo, and the immune activation effect in vivo, it was verified that the polypeptide can block the PD-1/PD-L1 signaling pathway and activate T cells. immune response, with antitumor effect. The polypeptide of the present invention can be prepared by a solid-phase synthesis method, and has the advantages of low manufacturing cost, high stability, low immunogenicity and better organ or tumor penetration ability compared with monoclonal antibodies and small molecule compounds. |
| priorityDate | 2022-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 122.